Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFG316 in neovascular age-related macular degeneration
NCT01624636Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2012
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tesidolumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Dec 2012; status: terminated.
02
Drugs
tesidolumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01624636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01624636.